Cargando…
Vascular Endothelial Growth Factor and Its Soluble Receptor in Systemic Lupus Erythematosus Patients
Vascular endothelial growth factor (VEGF) is a major regulator of physiological and pathological angiogenesis. Its soluble receptor (sVEGFR) is a potent VEGF antagonist. Systemic lupus erythematosus (SLE) is an autoimmune disease with a diverse array of clinical manifestations that affect virtually...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9775345/ https://www.ncbi.nlm.nih.gov/pubmed/36551311 http://dx.doi.org/10.3390/biom12121884 |
_version_ | 1784855621572493312 |
---|---|
author | Gómez-Bernal, Fuensanta Fernández-Cladera, Yolanda Quevedo-Abeledo, Juan Carlos García-González, María González-Rivero, Agustín F. de Vera-González, Antonia Martín-González, Candelaria González-Gay, Miguel Á. Ferraz-Amaro, Iván |
author_facet | Gómez-Bernal, Fuensanta Fernández-Cladera, Yolanda Quevedo-Abeledo, Juan Carlos García-González, María González-Rivero, Agustín F. de Vera-González, Antonia Martín-González, Candelaria González-Gay, Miguel Á. Ferraz-Amaro, Iván |
author_sort | Gómez-Bernal, Fuensanta |
collection | PubMed |
description | Vascular endothelial growth factor (VEGF) is a major regulator of physiological and pathological angiogenesis. Its soluble receptor (sVEGFR) is a potent VEGF antagonist. Systemic lupus erythematosus (SLE) is an autoimmune disease with a diverse array of clinical manifestations that affect virtually any organ. We aimed to analyze the relationship of VEGF and sVEGFR with SLE disease-related features including disease activity, damage, and severity. Serum levels of VEGF165 isoform and sVEGFR (receptor 1) were assessed in 284 well-characterized patients with SLE. Linear regression analysis was performed to analyze the relationship of disease characteristics with both VEGF and sVEGFR. Patients with a disease damage index (SLICC score) equal to or greater than 1 had significantly elevated serum levels of VEGF and sVEGFR. Regarding disease-specific features, musculoskeletal manifestations were the disease feature most commonly associated with the upregulation of both VEGF and sVEGFR. SLE disease damage is associated with higher levels of VEGF and sVEGFR. |
format | Online Article Text |
id | pubmed-9775345 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-97753452022-12-23 Vascular Endothelial Growth Factor and Its Soluble Receptor in Systemic Lupus Erythematosus Patients Gómez-Bernal, Fuensanta Fernández-Cladera, Yolanda Quevedo-Abeledo, Juan Carlos García-González, María González-Rivero, Agustín F. de Vera-González, Antonia Martín-González, Candelaria González-Gay, Miguel Á. Ferraz-Amaro, Iván Biomolecules Article Vascular endothelial growth factor (VEGF) is a major regulator of physiological and pathological angiogenesis. Its soluble receptor (sVEGFR) is a potent VEGF antagonist. Systemic lupus erythematosus (SLE) is an autoimmune disease with a diverse array of clinical manifestations that affect virtually any organ. We aimed to analyze the relationship of VEGF and sVEGFR with SLE disease-related features including disease activity, damage, and severity. Serum levels of VEGF165 isoform and sVEGFR (receptor 1) were assessed in 284 well-characterized patients with SLE. Linear regression analysis was performed to analyze the relationship of disease characteristics with both VEGF and sVEGFR. Patients with a disease damage index (SLICC score) equal to or greater than 1 had significantly elevated serum levels of VEGF and sVEGFR. Regarding disease-specific features, musculoskeletal manifestations were the disease feature most commonly associated with the upregulation of both VEGF and sVEGFR. SLE disease damage is associated with higher levels of VEGF and sVEGFR. MDPI 2022-12-15 /pmc/articles/PMC9775345/ /pubmed/36551311 http://dx.doi.org/10.3390/biom12121884 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Gómez-Bernal, Fuensanta Fernández-Cladera, Yolanda Quevedo-Abeledo, Juan Carlos García-González, María González-Rivero, Agustín F. de Vera-González, Antonia Martín-González, Candelaria González-Gay, Miguel Á. Ferraz-Amaro, Iván Vascular Endothelial Growth Factor and Its Soluble Receptor in Systemic Lupus Erythematosus Patients |
title | Vascular Endothelial Growth Factor and Its Soluble Receptor in Systemic Lupus Erythematosus Patients |
title_full | Vascular Endothelial Growth Factor and Its Soluble Receptor in Systemic Lupus Erythematosus Patients |
title_fullStr | Vascular Endothelial Growth Factor and Its Soluble Receptor in Systemic Lupus Erythematosus Patients |
title_full_unstemmed | Vascular Endothelial Growth Factor and Its Soluble Receptor in Systemic Lupus Erythematosus Patients |
title_short | Vascular Endothelial Growth Factor and Its Soluble Receptor in Systemic Lupus Erythematosus Patients |
title_sort | vascular endothelial growth factor and its soluble receptor in systemic lupus erythematosus patients |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9775345/ https://www.ncbi.nlm.nih.gov/pubmed/36551311 http://dx.doi.org/10.3390/biom12121884 |
work_keys_str_mv | AT gomezbernalfuensanta vascularendothelialgrowthfactoranditssolublereceptorinsystemiclupuserythematosuspatients AT fernandezcladerayolanda vascularendothelialgrowthfactoranditssolublereceptorinsystemiclupuserythematosuspatients AT quevedoabeledojuancarlos vascularendothelialgrowthfactoranditssolublereceptorinsystemiclupuserythematosuspatients AT garciagonzalezmaria vascularendothelialgrowthfactoranditssolublereceptorinsystemiclupuserythematosuspatients AT gonzalezriveroagustinf vascularendothelialgrowthfactoranditssolublereceptorinsystemiclupuserythematosuspatients AT deveragonzalezantonia vascularendothelialgrowthfactoranditssolublereceptorinsystemiclupuserythematosuspatients AT martingonzalezcandelaria vascularendothelialgrowthfactoranditssolublereceptorinsystemiclupuserythematosuspatients AT gonzalezgaymiguela vascularendothelialgrowthfactoranditssolublereceptorinsystemiclupuserythematosuspatients AT ferrazamaroivan vascularendothelialgrowthfactoranditssolublereceptorinsystemiclupuserythematosuspatients |